NmVac4-A/C/Y/W-135

NmVac4-A/C/Y/W-135 is a vaccine used to prevent meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. It is a conjugate vaccine, which means it contains bacterial antigens linked to a protein carrier. This vaccine is recommended for individuals who are at increased risk of meningococcal disease, including travelers to certain parts of the world, military recruits, and people with certain medical conditions.

Composition

NmVac4-A/C/Y/W-135 is composed of four purified capsular polysaccharide antigens from Neisseria meningitidis serogroups A, C, Y, and W-135, each conjugated to diphtheria toxoid protein carrier. The vaccine is supplied as a sterile solution for intramuscular injection.

Indications

NmVac4-A/C/Y/W-135 is indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y, and W-135. The vaccine is recommended for individuals 2 years of age and older who are at increased risk of meningococcal disease.

Contraindications

NmVac4-A/C/Y/W-135 is contraindicated in individuals with a history of severe allergic reaction to any component of the vaccine or to diphtheria toxoid.

Side Effects

Common side effects of NmVac4-A/C/Y/W-135 include pain at the injection site, fatigue, headache, muscle pain, and chills. Serious side effects are rare but can include severe allergic reactions.

Dosage

The recommended dosage of NmVac4-A/C/Y/W-135 is a single 0.5 mL dose administered intramuscularly. The need for revaccination has not been determined.

Storage

NmVac4-A/C/Y/W-135 should be stored at 2-8°C (36-46°F). Do not freeze. Discard if the vaccine has been frozen.

See Also

• Meningococcal vaccine
• Neisseria meningitidis
• Vaccine
• Meningococcal disease

NmVac4-A/C/Y/W-135 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia